Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.comSponsors
CROs
CDMOs
Couriers
Advocacy Groups
Venture Capitalists
Medical Societies
Physicians
Advancing the field of cancer Theranostics requires a multitude of industries working together. Companies provide discovery, development, production, clinical trial management, radioactive courier services, equipment suppliers, staffing, dosimetry, capital investment, regulatory agencies, cancer centers, and many more.
View EcosystemTheranosticTrials was developed through the collaboration of 2 key opinion leaders in the field of Radiopharmaceuticals. Drs. Luke Nordquist and Oliver Sartor saw the need for a such a web-based tool to provide patient education & ultimately improve access to the rapidly expanding field of radiopharmaceutical clinical trials. Patients globally are seeking access to these highly sought-after clinical trials which are providing new hope.
Distinguished Investigator
A Distinguished Investigator of Theranostics is a level of distinction conferred upon an individual physician who has demonstrated a mastery of conducting novel radioligand therapies and molecular imaging clinical trials.
RADIOLIGAND THERAPY (RLT) is a highly effective approach to very accurately locating cancer cells and effectively killing those same cells by delivery various radioisotopes to a specific target that is located on a type of cancer. Some of the Radioisotopes are diagnostic for locating cancers & some therapeutic to treat the cancers.
There are several Components to a RLT that are simply demonstrated in the truck diagram including:
To learn more about the specific components being studied today on clinical trials around the world check out the RLT COMPONENTS Tab.
View All
Help us improve your experience